Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Antimicrob Agents Chemother
; 61(12)2017 12.
Article
em En
| MEDLINE
| ID: mdl-28993338
ABSTRACT
Ceftolozane-tazobactam (C/T) and ceftazidime-avibactam (CZA) MICs were evaluated for a collection of 309 beta-lactam-resistant isolates of Pseudomonas aeruginosa recovered from three institutions in the area of Los Angeles, CA. Overall, 12.0% of isolates were susceptible to imipenem, 15.9% were susceptible to meropenem, 20.7% were susceptible to piperacillin-tazobactam, 24.6% were susceptible to ceftazidime, 25.9% were susceptible to cefepime, 72.5% were susceptible to C/T, and 61.8% were susceptible to CZA. Among C/T-resistant isolates, 9.1% were CZA susceptible, whereas 36.4% of CZA-resistant isolates were susceptible to C/T.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pseudomonas aeruginosa
/
Beta-Lactamases
/
Ceftazidima
/
Cefalosporinas
/
Ácido Penicilânico
/
Resistência beta-Lactâmica
/
Compostos Azabicíclicos
/
Antibacterianos
Tipo de estudo:
Clinical_trials
Limite:
Humans
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article